Speakers

After completing a PhD in synthetic chemistry in the Royal College of Surgeons, Dublin, Colm took up a postdoctoral position in the Leiden Institute of Chemistry, modelling metalloenzymes. Following this, since late 1997, Colm has been working in the pharma industry, in chemical development and manufacturing roles, across big pharma and CDMOs, before joining BioMarin in 2010, where he now leads drug substance development and manufacturing, for early phase (toxicology to P3) synthetic molecules. Colm is a seasoned manufacturing development chemist, leading groups, often through organisational change, to deliver synthetic molecule strategies, in alignment with corporate goals and requirement.

Presentation Title: Challenges in developing an effective CDMO operating model, as the organisation grows in size and complexity

Abstract: Colm will elaborate some of the challenges an organisation can experience as it grows and matures, with regard to managing an ever-growing and ever-differentiating CDMO network.  Key strategic questions will be discussed, supported by real life case studies

View company profile